Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) EBIT Margin: 2013-2017

Historic EBIT Margin for Tvardi Therapeutics (TVRD) over the last 2 years, with Mar 2017 value amounting to -2,450.60%.

  • Tvardi Therapeutics' EBIT Margin rose 15449225.00% to -2,450.60% in Q1 2017 from the same period last year, while for Mar 2017 it was -2,029.07%, marking a year-over-year decrease of 120345.00%. This contributed to the annual value of -67,906.98% for FY2016, which is 6724466.00% down from last year.
  • According to the latest figures from Q1 2017, Tvardi Therapeutics' EBIT Margin is -2,450.60%, which was up 85.47% from -16,868.35% recorded in Q2 2016.
  • Over the past 5 years, Tvardi Therapeutics' EBIT Margin peaked at -205.29% during Q3 2015, and registered a low of -156,942.86% during Q1 2016.
  • Over the past 3 years, Tvardi Therapeutics' median EBIT Margin value was -1,707.71% (recorded in 2015), while the average stood at -29,681.29%.
  • Per our database at Business Quant, Tvardi Therapeutics' EBIT Margin crashed by 15,597,803bps in 2016 and then soared by 15,449,225bps in 2017.
  • Quarterly analysis of 5 years shows Tvardi Therapeutics' EBIT Margin stood at -216.34% in 2013, then tumbled by 25,806bps to -474.40% in 2014, then soared by 38,165bps to -205.29% in 2015, then slumped by 1,621,252bps to -16,868.35% in 2016, then surged by 15,449,225bps to -2,450.60% in 2017.
  • Its EBIT Margin was -2,450.60% in Q1 2017, compared to -16,868.35% in Q2 2016 and -156,942.86% in Q1 2016.